Results 11 to 20 of about 312,815 (269)
Exercise for intermittent claudication [PDF]
Cochrane Database of Systematic Reviews, 1969 Exercise programmes are a relatively inexpensive, low-risk option compared with other more invasive therapies for leg pain on walking (intermittent claudication (IC)). This is an update of a review first published in 1998.The prime objective of this review was to determine whether an exercise programme in people with intermittent claudication was ...
GC Leng, B Fowler, E. Ernst
+11 more sources
Neurogenic Intermittent Claudication [PDF]
Proceedings of the Royal Society of Medicine, 1964 W. A. Bourne
+14 more sources
Cilostazol for intermittent claudication. [PDF]
Cochrane Database Syst Rev, 2021 Peripheral arterial disease (PAD) affects between 4% and 12% of people aged 55 to 70 years, and 20% of people over 70 years. A common complaint is intermittent claudication (exercise-induced lower limb pain relieved by rest). These patients have a three- to six-fold increase in cardiovascular mortality.
Brown T +5 more
europepmc +10 more sources
Buflomedil for intermittent claudication [PDF]
Cochrane Database of Systematic Reviews, 2000 Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined.To evaluate the available evidence on the efficacy ...
TLM de Backer +2 more
+10 more sources
Intermittent claudication [PDF]
BMJ, 2007 A 58 year old smoker presented with a six month history of pain in the left calf during walking.
Roger W, Simon +3 more
openaire +4 more sources
Intermittent claudication [PDF]
Current Treatment Options in Cardiovascular Medicine, 2001 Intermittent claudication is the most common symptom in patients with peripheral arterial disease (PAD). As such, it is mandatory for clinicians to treat both the PAD-specific symptoms (to decrease functional impairment and thereby improve quality- of-life, as well as to decrease rates of amputation) and the underlying systemic atherosclerosis (and ...
Alan T., Hirsch, Laura, M Reich
openaire +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2022 Background The COMPASS trial demonstrated that in patients with peripheral arterial disease, the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major adverse limb events, but it is not known whether this combination can ...
Eduardo Ramacciotti MD, PhD +16 more
doaj +1 more source
Intermittent Claudication and Asymptomatic Peripheral Arterial Disease.
Deutsches Ärzteblatt International, 2020 BACKGROUND The conservative treatment of peripheral arterial disease (PAD), as recommended in current guidelines, encompasses measures such as lifestyle modification and risk-factor management.
G. Rümenapf +3 more
semanticscholar +1 more source
Naftidrofuryl for intermittent claudication [PDF]
Cochrane Database of Systematic Reviews, 2008 Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial.To evaluate evidence on the efficacy and safety of oral ...
Luc M. Van Bortel +4 more
openaire +4 more sources